Atrial peptide clearance inhibitors

Drug Profile

Atrial peptide clearance inhibitors

Latest Information Update: 18 Jul 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scios
  • Developer Bayer; Scios
  • Class
  • Mechanism of Action Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Heart failure; Hypertension

Most Recent Events

  • 18 Jul 2001 No-Development-Reported for Congestive heart failure in USA (PO)
  • 18 Jul 2001 No-Development-Reported for Hypertension in USA (PO)
  • 12 May 1997 Preclinical development for Congestive heart failure in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top